Articles tagged "Malignancy"

2022 American Transplant Congress
Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International Multicenter Analysis
M. L. Holzner¹, V. Mazzaferro², M. Droz dit Busset², L. Aldrighetti³, F. Ratti³, K. Hasegawa⁴, J. Arita⁴, G. Sapisochin⁵, P. Abreu⁵, W. Schoening⁶, N. Nevermann⁶, M. Schmelzle⁶, J. Pratschke⁶, S. Florman¹, K. Halazun⁷, M. E. Schwartz¹, P. Tabrizian¹
¹Recanati/Miller Transplantation Institute, Mount Sinai, New York, NY, ²University of Milan, Milan, Italy, ³San Raffaele Hospital, Milan, Italy, ⁴University of Tokyo, Tokyo, Japan, ⁵University of Toronto, Toronto, ON, Canada, ⁶Charite University, Berlin, Germany, ⁷Weill Cornell Medical Center, New York, NY
*Purpose: Recurrence of intrahepatic cholangiocarcinoma (ICC) after liver resection (LR) remains high and optimal therapy for recurrent ICC is challenging. Herein we assess the outcomes…
2022 American Transplant Congress
De Novo Fibrinogen Alpha Chain Amyloidosis in Kidney Allograft
T. Khaja¹, L. Truong², G. Nassar¹
¹Nephrology, Houston Methodist Hospital, Houston, TX, ²Pathology, Houston Methodist Hospital, Houston, TX
*Purpose: Amyloidosis is a disorder characterized by tissue deposition of misfolded proteins that can lead to organ damage such as renal failure. There are multiple…
2022 American Transplant Congress
Transplant Combined with Neoadjuvant Therapy Improves Survival for Patients with Liver-Limited, Locally Advanced Intrahepatic Cholangiocarcinoma: A SEER Database Analysis
G. G. Panayotova¹, M. Javle², S. Pentakota¹, F. Paterno¹, A. Amin¹, L. Brown¹, S. Simonishvili¹, Y. Qin¹, T. Ayorinde¹, G. Prakash¹, C. Conrad³, J. V. Guarrera¹, K. E. Lunsford¹
¹Rutgers New Jersey Medical School, Newark, NJ, ²University of Texas, MD Anderson Cancer Center, Houston, TX, ³St. Elizabeth's Medical Center, Boston, MA
*Purpose: Preliminary single-center data suggest multimodal therapy may improve outcomes for patients with intrahepatic cholangiocarcinoma (iCCA) undergoing liver transplant (LT), particularly in the setting of…
2022 American Transplant Congress
Metastatic BK Virus-Associated Urothelial Carcinoma Originating in Renal Allograft
J. Torrealba¹, H. Jones¹, A. Bhakta², L. Jia¹, D. Wojciechowski²
¹Pathology, UT Southwestern, Dallas, TX, ²Internal Medicine, UT Southwestern, Dallas, TX
*Purpose: Cases of urinary tract carcinoma associated with BK virus have been reported in kidney transplant recipients; therefore, we postulate that BK virus may play…
2022 American Transplant Congress
Seroprevalence of HHV8 Among Donors and Recipients with HIV
P. H. Nambiar¹, T. Liang², J. D. Motter³, W. Werbel³, S. Mehta⁴, V. Kirchner⁵, M. Rana⁶, S. Florman⁷, J. Odim⁸, W. Miley⁹, N. Labo⁹, D. Whitby⁹, A. Massie¹⁰, D. Segev³, A. Tobian³, C. Durand²
¹Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, ²Medicine, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴New York University Langone Transplant Institute, New York, NY, ⁵University of Minnesota, Minneapolis, MN, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Mount Sinai Medical Center, New York, NY, ⁸National Institute of Health, Bethesda, MD, ⁹National Cancer Institute, Frederick, MD, ¹⁰Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: Kaposi sarcoma (KS) can develop post-transplant via recipient HHV8 reactivation or donor-acquired HHV8. In the general US population, HHV8 seroprevalence is low (1-5%), yet…
2022 American Transplant Congress
Cutaneous Angiosarcoma in Solid Organ Transplant Recipients – Novel Case & Review of the Literature
S. M. Elzein, R. R. Caplan
Houston Methodist Hospital, Houston, TX
*Purpose: Cutaneous angiosarcoma, a rare and extremely aggressive malignant neoplasm, has been described in fewer than twenty-five solid organ transplant recipients to date. Secondary, or…
2021 American Transplant Congress
Treg Lymphotoxin Engages Lymphotoxin Receptor on Cancer and Endothelial Cells to Promote Cancer Metastatic Migration: Mechanisms for Treg-Cancer Interactions
W. Piao, R. Oakes, C. Paluskievicz, J. Christopher, J. Bromberg
U Maryland, Baltimore, MD
*Purpose: Treg immune suppression which is critical for transplant graft survival may also enhance tumor growth and metastases. Treg lymphotoxin (LTα1β2) may directly engage the…
2021 American Transplant Congress
Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term
T. Schachtner, J. Fuhrmann, T. Mueller
Nephrology, University Hospital Zurich, Zurich, Switzerland
*Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…
2021 American Transplant Congress
Impact of Donation After Circulatory Death Donor Allografts on Outcomes Following Liver Transplantation for Cholangiocarcinoma
S. Kumar¹, S. Lin², J. D. Schold²
¹Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ²Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Improvements in the management of extra-hepatic cholangiocarcinoma (CCA) resulted in allocation of a standardized model for end-stage liver disease (MELD) exception score for liver…
2021 American Transplant Congress
Excellent Pathological Response with Gemcitabine-based Protocol in Patient with Hilar Cholangiocarcinoma
A. Saharia¹, R. McMillan¹, S. Kodali¹, M. Javley², C. M. Mobley¹, M. J. Hobeika¹, A. Shetty¹, D. W. Victor¹, R. McFadden¹, M. Abdelrahim¹, K. Heyne¹, A. O. Gaber¹, R. M. Ghobrial¹
¹Houston Methodist Hospital, Houston, TX, ²MD Anderson Cancer Center, Houston, TX
*Purpose: The standard treatment for hilar cholangiocarcinoma is using 5FU along with brachytherapy and external beam radiation. The downside of this regimen is the uncertain…